Results 151 to 160 of about 156,514 (326)
The therapeutic oxymoron: exploring the mechanisms of open-label placebo
Placebos have emancipated themselves from earlier, often unethical or merely research- based practices, toward an open and thereby ethical administration. Despite a plethora of efficacy studies and nearly two decades of empirical research on open-label placebos (OLPs), little to nothing is known about the circumstances under which they realize their ...
openaire +2 more sources
This study introduces a framework that combines graph neural networks with causal inference to forecast recurrence and uncover the clinical and pathological factors driving it. It further provides interpretability, validates risk factors via counterfactual and interventional analyses, and offers evidence‐based insights for treatment planning ...
Jubair Ahmed +3 more
wiley +1 more source
Open label placebo: pill and needle
Dha-Hyun Choi +2 more
openaire +2 more sources
ABSTRACT Postpartum hemorrhage (PPH) remains the leading cause of preventable maternal mortality despite standard interventions. Recent fibrinogen trials failed to improve outcomes, prompting interest in coagulation factor XIII (FXIII). FXIII functions as “molecular cement,” cross‐linking fibrin and stabilizing clots.
Jeremy W. Jacobs +8 more
wiley +1 more source
Anne Schienle, Arved Seibel Department of Clinical Psychology, University of Graz, Graz, AustriaCorrespondence: Anne Schienle, Email anne.schienle@uni-graz.atBackground: Open-label placebos (OLPs), honestly prescribed regarding their inert nature, have ...
Schienle A, Seibel A
doaj
Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension [PDF]
Michael G. Aman +12 more
openalex +1 more source
ABSTRACT Acute chest syndrome (ACS) is one of the most common severe complications of sickle cell disease (SCD). In recent years, a major role of inflammation and innate immunity has been evidenced, but ACS pathophysiology remains incompletely understood, and therapeutic options are limited.
Slimane Allali +14 more
wiley +1 more source
Attitudes towards open‐label versus placebo‐control designs in oncology randomized trials: A survey of medical oncologists [PDF]
Igal Kushnir +4 more
openalex +1 more source
ABSTRACT A comprehensive synthesis of the broad range of neurodevelopmental and psychiatric manifestations in NF1 is needed to identify knowledge gaps and future directions for NF1 research. In the following scoping review, we identify and summarize the scope of research that examines neurodevelopmental and psychiatric manifestations, both as ...
Meera Chopra +5 more
wiley +1 more source
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease often associated with asthma. The global airway hypothesis suggests bidirectional inflammatory interactions between upper and lower airways. Mepolizumab, an anti–IL‐5 therapy, treats conditions systemically, while functional endoscopic sinus surgery ...
Jens Tidemandsen +9 more
wiley +1 more source

